Your browser doesn't support javascript.
loading
Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers.
Martinón-Torres, Federico; Diez-Domingo, Javier; Feroldi, Emmanuel; Jordanov, Emilia; B'Chir, Siham; Da Costa, Xavier.
Afiliação
  • Martinón-Torres F; From the Hospital Clínico Universitario de Santiago de Compostela, A Choupana, Santiago de Compostela, Spain.
  • Diez-Domingo J; Vaccine Research Department, FISABIO-Public Health, Av da Cataluña, Valencia, Spain.
  • Feroldi E; Global Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France.
  • Jordanov E; Global Clinical Sciences, Sanofi Pasteur Inc., Discovery Drive, Swiftwater, Pennsylvania.
  • B'Chir S; Biostatistics Department, Sanofi Pasteur, Marcy l'Etoile, France.
  • Da Costa X; Global Clinical Immunology, Sanofi Pasteur Inc., Discovery Drive, Swiftwater, Pennsylvania.
Pediatr Infect Dis J ; 38(3): 317-322, 2019 03.
Article em En | MEDLINE | ID: mdl-30408001
ABSTRACT

BACKGROUND:

This study assessed a pediatric mixed hexavalent diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae b [polyribosylribitol phosphate (PRP-T)]-pentavalent (DTaP-IPV//PRP-T)-hexavalent primary series schedule followed by a pentavalent booster.

METHODS:

Healthy infants (N = 265) who had received a prior HB vaccination received a fully liquid, hexavalent vaccine (DTaP-IPV-HB-PRP-T) at 2 and 6 months of age and a reconstituted pentavalent vaccine (DTaP-IPV//PRP-T) at 4 months of age. Coadministered vaccines were pneumococcal vaccine at 2 and 4 months (and optionally at 6 months of age), rotavirus vaccine at 2, 4, 6 months and meningococcal serogroup C vaccine at 2 months. At 18 months, participants received DTaP-IPV//PRP-T and pneumococcal vaccine boosters. Immunogenicity was assessed using validated assays and safety by parental reports.

RESULTS:

For the hexavalent and pentavalent vaccines, the primary series and booster immune responses in terms of seroprotection and vaccine response rates were high for all antigens (generally > 99% and > 95% for the primary series and booster, respectively) and prebooster antibody persistence was good for all antigens (in particular, 92.4% of participants had prebooster anti-HB antibody ≥ 10 mIU/mL). The incidence of solicited reactions was lower after the booster vaccination (56.9%-73.1%) than the primary series (76.6%-97.4%); there were few vaccine-related unsolicited adverse events (1.9% and 1.5% for the primary series and booster, respectively), none led to participant discontinuation and none was serious.

CONCLUSIONS:

This study provides data that allow recommending authorities to consider the use of a sequential hexavalent-pentavalent-hexavalent primary vaccination series followed by a pentavalent booster in coadministration with other common childhood vaccines.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina Antipólio de Vírus Inativado / Vacina contra Difteria, Tétano e Coqueluche / Esquemas de Imunização / Imunização Secundária / Vacinas contra Hepatite B / Vacinas Anti-Haemophilus / Imunogenicidade da Vacina Tipo de estudo: Clinical_trials Limite: Female / Humans / Infant / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina Antipólio de Vírus Inativado / Vacina contra Difteria, Tétano e Coqueluche / Esquemas de Imunização / Imunização Secundária / Vacinas contra Hepatite B / Vacinas Anti-Haemophilus / Imunogenicidade da Vacina Tipo de estudo: Clinical_trials Limite: Female / Humans / Infant / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article